Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma

Figures & data

Table 1 Patient characteristics

Characteristic	Value
Total number of patients	60
Age, years (range)	60.5 (19–94)
Sex
Male/female (%)	34 (56)/26 (44)
Ann Arbor stage
I/II/III/IV (%)	3 (5)/9 (15)/16 (26.7)/32 (53.3)
NCCN-IPI score
0–1/2–3/4–5/6–8 (%)	6 (10)/20 (33.3)/27 (45)/7 (11.6)
Subtype
GCB/non-GCB, pts (%)	25 (41.6)/35 (58.4)
LDH U/L (range)	431.8 (87–3061)
Ki-67 (range)	57% (20–95%)
Bone marrow involvement, pts (%)	6 (10)
Extranodal involvement, pts (%)	37 (61.6)

The NCCN-IPI uses a maximum of eight points for the categories age [>40–60 (one point), >60–75 (two points), >75 years (three points)], Ann Arbor stage III/IV disease (one point), LDH ratio >1 (one point) and >3 times (two points) the upper limit of normal, extranodal disease in major organs (one point), and Eastern Cooperative Oncology Group (ECOG) performance status ≥2 (one point).

Table 2 Spearman rank correlation analysis of the relation between F-18 FDG PET/CT quantization parameters and patient clinical characteristics

	Suvmax		MTV		TLG		No. of enlarged lymph nodes
	rs	P-value	rs	P-value	rs	P-value	rs	P-value
SUVmax	–	–	0.326	0.011	0.471	0.008	0.140	0.285
MTV	–	–	–	–	0.966	0.003	0.613	0.010
TLG	–	–	–	–	–	–	0.557	0.007
Age	−0.001	0.993	−0.058	0.654	−0.002	0.984	−0.024	0.854
Ann Arbor Stage	0.067	0.606	0.334	0.009	0.361	0.004	0.121	0.356
NCCN-IPI	0.188	0.149	0.386	0.002	0.445	0.000	0.197	0.129
LDH	0.093	0.479	0.557	0.000	0.564	0.000	0.369	0.003
Ki-67	0.253	0.051	−0.024	0.855	0.024	0.855	0.117	0.371

Table 3 Univariate Cox proportional hazard regression analysis

	HR	95%CI	P-value
SUVmax (1 × 10)	1.047	0.968–1.132	0.245
GCB subgroup	0.875	0.499–1.533	0.641
Non-GCB subgroup	1.041	0.963–1.124	0.310
MTV (1 × 10^Citation2)	1.030	1.017–1.044	0.000
GCB subgroup	1.028	1.005–1.052	0.017
Non-GCB subgroup	1.076	1.034–1.119	0.002
TLG (1 × 10^Citation3)	1.078	1.042–1.116	0.000
GCB subgroup	1.079	1.020–1.141	0.008
Non-GCB subgroup	1.128	1.056–1.204	0.001
Number of enlarged lymph nodes (>2 cm)	1.108	1.031–1.191	0.005
NCCN-IPI	1.577	1.141–2.181	0.006
LDH	1.000	0.999–1.001	0.219
Ki-67	0.734	0.088–6.097	0.775

Table 4 Multivariate Cox proportional hazard regression analysis adjusted by NCCN-IPI

	HR	95%CI	P-value
SUVmax (1 × 10)	1.058	0.961–1.166	0.251
MTV (1 × 10^Citation2)	1.028	1.014–1.043	0.001
TLG (1 × 10^Citation3)	1.071	1.032–1.112	0.001
Number of enlarged lymph nodes (>2 cm)	1.089	1.014–1.169	0.018

Figure 1 Kaplan–Meier survival analysis of PFS in B-cell lymphoma according to MTV value.

Figure 2 Kaplan–Meier survival analysis of PFS in B-cell lymphoma according to TLG value.

Figure 3 Kaplan–Meier survival analysis of PFS in B-cell lymphoma according to number of enlarged lymph nodes.

Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505. doi: 10.1182/asheducation-2011.1.498

 PubMed Web of Science ®Google Scholar

Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94. doi: 10.1056/NEJM199309303291402

 PubMed Web of Science ®Google Scholar